Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Influenza
Cidara's Phase IIb flu prevention data tops prophylactic effect typically seen with vaccines • Source: Shutterstock

Cidara Therapeutics’ business outlook improved substantially on June 23 after releasing pre-market Phase IIb data for its non-vaccine seasonal influenza prevention agent showing better prophylaxis capabilities than usually seen with flu shots. The San Diego firm said on a same-day call that it hopes to convene end-of-Phase II talks with the US Food and Drug Administration soon to plan a pivotal study.

Key Takeaways
  • Cidara unveiled Phase IIb data for its non-vaccine flu prevention agent CD388 showing statistical significance for preventive efficacy at three tested doses.

The positive topline Phase IIb data for CD388, a drug-Fc conjugate (DFC), provide validation for Cidara’s change of course in...

More from Strategy

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By 

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

More from Therapy Areas

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.